The Mayo Clinic Cancer Center (MCCC) provides oversight for the scientific aspects and performance of cancer interventional clinical trials conducted at Mayo Clinic through the Center's Protocol Review and Monitoring System (PRMS). The focus of the PRMS is on scientific merit, priorities, and progress of the clinical research protocols conducted at the MCCC. The Scientific Review Committee (SRC) uses a consistent and defined process for scientific review that is achieved through established written review criteria, common reporting forms, and defined expectations. The SRC has responsibility for the approval and/or disapproval of each study, as well as for the final decision concerning prioritization. To accommodate the increasing complexity and volume of trials, 4 SRC subcommittees cover trials in hematology and solid tumors with drug- predominant therapy, radiation-predominant therapy, and surgery-predominant therapy, respectively. Another subcommittee of the SRC, the Scientific Progress Review Subcommittee (SPRC), reviews modifications and amendments for approved and active studies. If the modification or amendment proposes significant changes to the scientific components of a trial, SPRC may request that the SRC review the change and determine if it is appropriate for the trial to remain active and for the modification or amendment to be implemented. SPRC also monitors accrual to interventional trials to ensure adequate scientific progress. If accrual is not adequate, SPRC will initially work with the investigator to determine the reasons. If progress is not made and there is no reasonable expectation that changes will occur, SPRC forwards the study to SRC for consideration of closure. The MCCC PRMS is under the governance of the MCCC Clinical Research Committee, which is chaired by the Deputy Director for Clinical Research. The Clinical Research Committee reviews and approves the leadership and membership of each SRC subcommittee at least annually. It also provides guidance on standard scientific review and administrative processes for SRC and SPRC and reviews the metrics from these committees quarterly.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113629
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications